Your new post is loading...
Your new post is loading...
BigField GEG Tech's insight:
Here the scientists report the development of a novel platform to enhance the efficacy and safety of follicular lymphoma (FL) treatment. These studies raise the possibility of personalized treatment of lymphomas using a private antibody binding ligand that can be obtained in a few weeks.
BigField GEG Tech's insight:
Immunogenicity of AAV vectors renders repeated AAV dosing ineffective. Here the authors show that coadministration of nanoparticle-encapsulated rapamycin overcomes AAV immunogenicity through Treg induction, enabling efficient AAV redosing in mice and nonhuman primates.
BigField GEG Tech's insight:
Integration-defective lentiviral vectors (IDLVs) have become an important alternative
BigField GEG Tech's insight:
In an animal model of spinal cord injury, 2.5 weeks of exposure to a novel gene therapy led to improvements in motor tasks; longer exposure to the gene therapy (eight weeks) led to more significant improvement — the rats could perform more complex functions such as grasping and retrieving sugar pellets with their paws.
Torque Therapeutics, a biotech company in Cambridge, Massachusetts, announced its high-efficiency T-cell manufacturing process called Slipstream.
BigField GEG Tech's insight:
Proud to see one of our users at the cusp of implementing its ambitious CAR-T manufacturing project!
Viral Vectors and Plasmid DNA Manufacturing Market, 2030
BigField GEG Tech's insight:
The Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030 report offers a comprehensive study of the current scenario of manufacturing of viral and non-viral vectors that are primarily used for the development of gene therapies and T-cell therapies. The study features an in-depth analysis, highlighting the capabilities of a diverse set of players, covering both contract manufacturers and companies with in-house capabilities.
BigField GEG Tech's insight:
This chapter describes the potential use of viral-mediated gene transfer in the central nervous system for genome editing in the context of Huntington’s disease. Here, the scientist provide protocols that cover the design of various genome editing strategies, the cloning of CRISPR/Cas9 elements into lentiviral vectors, and the assessment of cleavage efficiency, as well as potential unwanted effects.
BigField GEG Tech's insight:
Correcting a genetic mutation lets beta thalassemia patients make healthy blood cells.
BigField GEG Tech's insight:
UNC School of Medicine scientists led by Aravind Asokan, PhD, reveal how certain gene-carrying AAV vectors can penetrate the brain more efficiently to treat brain and spinal cord conditions, while reducing liver payload.
BigField GEG Tech's insight:
The ANCHOR breakthrough technology developed by NeoVirTech allows real time visualisation and quantification of virus and viral vector infection/transduction and replication in living cells. This innovative system allows to tag the virus genomes and to visualize their cycle with an extreme accuracy.
BigField GEG Tech's insight:
NeoVirTech et GEG Tech annoncent la validation de la technologie ANCHORTM pour une forme modifiée du virus du SIDA. La technologie ANCHORTM développée par NeoVirTech permet de marquer l’ADN de virus et de visualiser son évolution en temps réel au sein de cellules vivantes. Il a été intégré avec succès par GEG Tech dans un virus dérivé du SIDA.
BigField GEG Tech's insight:
In this study, the scientists performed a forward genetic screen using Sleeping Beauty (SB) transposon insertional mutagenesis in mice treated to induce hepatic steatosis and compared the results to human HCC data. In humans, they determined that steatosis increased the proportion of female HCC patients, a pattern also reflected in mice. Their genetic screen identified 203 candidate steatosis-associated HCC genes, many of which are altered in human HCC and are members of established HCC-driving signaling pathways.
|
The company’s drug, PR-L201, is in development to treat Leukocyte Adhesion Deficiency-I, a rare pediatric disease.
BigField GEG Tech's insight:
Rocket Pharmaceuticals announced Monday (November 19) its gene therapy drughas been cleared by the US Food and Drug Administration (FDA) ahead of schedule.
BigField GEG Tech's insight:
Oxford BioMedica, has signed a fifteen year lease on a new facility at its site in Oxford, UK-based, which when operational will more than double the firm’s bioprocessing capacity. The 7,800m2 facility – the fourth plant at the site – will contain four GMP clean room suites and two fill and finish suites for lentiviral vector production and will help feed demand for a market the firm expects to grow to $800 million by 2026.
AVROBIO announced positive preliminary data for its Phase 1/2 trial testing AVR-RD-01 gene therapy in patients with Fabry disease.
BigField GEG Tech's insight:
AVROBIO, a biotechnology company developing single-dose gene therapies for rare diseases, announced positive preliminary data for its Phase 1/2 clinical trial testing AVR-RD-01 gene therapy in patients with Fabry disease. AVR-RD-01 consists of a lentiviral vector (transporter) containing a functional copy of the GLA gene, the gene mutated in Fabry disease, that is used to modify hematopoietic stem cells of the patients.
BigField GEG Tech's insight:
Beautiful example using a lentiviral vector designed to investigate the morphology of lateral amygdala pyramidal neurons.
Restoration of vision after de novo genesis of rod photoreceptors in mammalian retinas - Nature
Click here to edit the content
BigField GEG Tech's insight:
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward regenerative therapies for blinding diseases such as age-related macular degeneration and retinitis pigmentosa. A report of the findings appears online today in Nature. NEI is part of the National Institutes of Health.
BigField GEG Tech's insight:
quick zap of electricity makes T cells more receptive to taking in new genetic material and gene-editing reagents, researchers report July 11 in Nature. The discovery could expedite protocols for creating immunotherapies to treat a range of cancers.
BigField GEG Tech's insight:
Here, the scientists report the development of an alternative safeguard for chimeric antigen receptor T-cell therapies. They have incorporated a safeguard component into a conventional CAR architecture that enables tight control over CAR T-cell activity and has the potential to improve their safety profile in clinical settings. In addition, the CubiCAR architecture is compatible with multiple scFvs designed against different targets, thus bearing the potential to improve the safety of CAR T-cell immunotherapies for a broad range of patients.
BigField GEG Tech's insight:
NeoVirTech and GEG Tech are proud to announce the first real-time visualization of HIV-1 vector in living cells. The ANCHORTM technology developed by NeoVirTech enables autonomous fluorescent tagging of any DNA fragment to follow its behavior in living cells. It was successfully integrated by GEG Tech in their Lenti-ONE vector based on HIV-1 virus. This result will i) open new research paths in the fight against HIV/AIDS, and ii) accelerate innovation in genetic engineering fields exploiting HIV-1 derived vectorization systems.
BigField GEG Tech's insight:
Bioverativ has agreed to license Oxford BioMedica’s LentiVector® Enabled technology, as well as its industrial-scale manufacturing technology for up to $105 million-plus
BigField GEG Tech's insight:
Scientists have developed a CRISPR gene-editing technique that can potentially correct a majority of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD) by making a single cut at strategic points along the patient's DNA, according to a study from UT Southwestern Medical Center.
BigField GEG Tech's insight:
In this study, scientists demonstrated that ICOS and 4-1BB ICD increase CARs efficacy in solid tumor models over current 4-1BB–based CAR and are promising therapeutics for clinical testing.
|
Your new post is loading...
The manufacture of large quantities of high-quality DNA is a major bottleneck in the production of viral vectors for gene therapy. Touchlight Genetics has developed a proprietary abiological technology that addresses the major issues in commercial DNA supply. The technology uses ‘rolling-circle’ amplification to produce large quantities of concatameric DNA that is then processed to create closed linear double-stranded DNA by enzymatic digestion. Here the scientists have demonstrated that functional lentiviral vectors can be produced using the novel dbDNA™ configuration for delivery in vitro and in vivo.